Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 9/20 | 0.64 |
| ▸ | MC4R | P32245 | 9/20 | 0.64 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325753 | 0.95 | MC1R (0.64) | MC1RMC4RMC5RMC3RITGB3 | |
| SCHEMBL1310203 | 0.92 | MC1R (0.65) | MC1RMC4RMC5RMC3RITGB3 | |
| SCHEMBL1310622 | 0.92 | MC1R (0.65) | MC1RMC4RMC5RMC3RITGB3 | |
| SCHEMBL20450424 | 0.92 | MC1R (0.65) | MC1RMC4RMC5RMC3RITGB3 | |
| SCHEMBL1325033 | 0.90 | MC4R (0.76) | MC1RMC4RMC5RMC3RITGB1 | |
| SCHEMBL15273371 | 0.90 | MC1R (0.62) | MC1RMC4RMC5RMC3RITGB3 | |
| SCHEMBL1325755 | 0.87 | MC4R (0.76) | MC1RMC4RMC5RMC3RITGB1 | |
| SCHEMBL20450387 | 0.86 | MC4R (0.66) | MC1RMC4RMC3R | |
| SCHEMBL1325007 | 0.86 | MC4R (0.66) | MC1RMC4RMC3R | |
| SCHEMBL20450360 | 0.86 | MC1R (0.78) | MC1RMC4RMC5RMC3RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | claimed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | claimed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | claimed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | claimed |
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-9610461-B2 | Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-04 | — | — | US | disclosed |
| EP-2790692-B1 | ASSOCIATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND OF A MC1R RECEPTOR AGONIST FOR TREATING AND/OR PREVENTING PIGMENTATION DISORDERS | GALDERMA RES & DEV (FR) | 2016-11-23 | — | — | EP | disclosed |
| US-9364455-B2 | Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-14 | — | — | US | disclosed |
| US-20150045719-A1 | COMBINATION OF A MC1R RECEPTOR AGONIST AND UVB FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-20140371147-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-12-18 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| EP-2790692-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | Galderma Research & Development (FR) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013087936-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-20 | — | — | WO | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010052253-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371147-A1 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | MC1R, MC3R, MC5R | MC1R 1/4885MC4R 7/4885MC5R 3/4885 |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | MC1R 326/4885MC4R 1479/4885MC5R 672/4885 |
| US-20150045719-A1 | COMBINATION OF A MC1R RECEPTOR AGONIST AND UVB FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS | MC1R, MC3R, MC5R | MC1R 1/4885MC4R 4/4885MC5R 3/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | MC1R 195/4885MC4R 873/4885MC5R 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.